Paolo Tarantino: Final iDFS results from NATALEE published in Annals of Oncology

Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, shared a post on X about a recent paper by Gabriel Hortobagyi et al. published in Annals of Oncology:

“Final iDFS results from NATALEE, previously presented at SABCS23, are now published in Annals of Oncology, showing a 3% delta in 3-year iDFS.

Things move fast, though: updated data were presented at ESMO24, with the delta rising to 5% at 4 years.”

“A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2− early breast cancer: final invasive disease–free survival results from the NATALEE trial”

Authors: Gabriel Hortobagyi, A. Lacko, J. Sohn, A. Chakravartty, D. Slamon et al..

More posts featuring Paolo Tarantino.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.